Do you want to read an article? Please log in or register.
Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
ImmunotherapyT Cells
Related content
T Cells
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis
Semin Cancer Biol.
Kumar P, Saini S, Prabhakar BS
doi: 10.1016/j.semcancer.
T CellsImmune Response
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
J Clin Oncol
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M
doi: 10.1200/JCO.21.01992
Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Ann Rheum Dis.
Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T
doi: 10.1136/annrheumdis-2020-217139.
COMMENTED
Immunotherapy
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
★ 3
Recommended and commented by
Prof. Dr Dr Sacha Rothschild, Faculty Member
Eur J Cancer
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O
doi: 10.1016/j.ejca.2021.03.010
Immunotherapy
Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
Front Oncol.
Le Bourgeois T, Strauss L, Aksoylar HI, Daneshmandi S, Seth P, Patsoukis N, Boussiotis VA
doi: 10.3389/fonc.2018.00237.
T Cells
Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer
J Autoimmun
Calabrese LH, Caporali R, Blank CU, Kirk AD
doi: 10.1016/j.jaut.2020.102546
Immunotherapy
The role of regulatory B cells in allergen immunotherapy
Curr Opin Allergy Clin Immunol.
van de Veen W
doi: 10.1097/
Immunotherapy
Long-term immune-related adverse events after discontinuation of immunotherapy
Immunotherapy
Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M
doi: 10.2217/imt-2020-0320
Melanoma and Skin Cancer
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
JAMA Dermatol.
Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T
doi: 10.1001/jamadermatol.